Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Wazir, U.; Mokbel, K. De-Escalation of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy. Eur. J. Breast Health 2022, 18, 6–12. [Google Scholar] [CrossRef]
- Brackstone, M.; Baldassarre, F.G.; Perera, F.E.; Cil, T.; Chavez Mac Gregor, M.; Dayes, I.S.; Engel, J.; Horton, J.K.; King, T.A.; Kornecki, A.; et al. Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J. Clin. Oncol. 2021, 39, 3056–3082. [Google Scholar] [CrossRef]
- Hughes, K.S.; Schnaper, L.A.; Bellon, J.R.; Cirrincione, C.T.; Berry, D.A.; McCormick, B.; Muss, H.B.; Smith, B.L.; Hudis, C.A.; Winer, E.P.; et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343. J. Clin. Oncol. 2013, 31, 2382–2387. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gentilini, O.; Veronesi, U. Staging the Axilla in Early Breast Cancer: Will Imaging Replace Surgery? JAMA Oncol. 2015, 1, 1031–1032. [Google Scholar] [CrossRef] [PubMed]
- Reimer, T.; Stachs, A.; Veselinovic, K.; Polata, S.; Muller, T.; Kuhn, T.; Heil, J.; Ataseven, B.; Reitsamer, R.; Hildebrandt, G.; et al. Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer. EClinicalMedicine 2023, 55, 101756. [Google Scholar] [CrossRef] [PubMed]
- Houssami, N.; Macaskill, P.; von Minckwitz, G.; Marinovich, M.L.; Mamounas, E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur. J. Cancer 2012, 48, 3342–3354. [Google Scholar] [CrossRef]
- von Minckwitz, G.; Untch, M.; Blohmer, J.U.; Costa, S.D.; Eidtmann, H.; Fasching, P.A.; Gerber, B.; Eiermann, W.; Hilfrich, J.; Huober, J.; et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 2012, 30, 1796–1804. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tadros, A.B.; Yang, W.T.; Krishnamurthy, S.; Rauch, G.M.; Smith, B.D.; Valero, V.; Black, D.M.; Lucci, A., Jr.; Caudle, A.S.; DeSnyder, S.M.; et al. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017, 152, 665–670. [Google Scholar] [CrossRef] [PubMed]
- Barron, A.U.; Hoskin, T.L.; Day, C.N.; Hwang, E.S.; Kuerer, H.M.; Boughey, J.C. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. JAMA Surg. 2018, 153, 1120–1126. [Google Scholar] [CrossRef] [Green Version]
- Shi, Z.Q.; Qiu, P.F.; Liu, Y.B.; Cong, B.B.; Zhao, T.; Chen, P.; Wang, C.J.; Zhang, Z.P.; Sun, X.; Wang, Y.S. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer. Breast J. 2019, 25, 1154–1159. [Google Scholar] [CrossRef]
- Samiei, S.; de Mooij, C.M.; Lobbes, M.B.I.; Keymeulen, K.; van Nijnatten, T.J.A.; Smidt, M.L. Diagnostic Performance of Noninvasive Imaging for Assessment of Axillary Response After Neoadjuvant Systemic Therapy in Clinically Node-positive Breast Cancer: A Systematic Review and Meta-analysis. Ann. Surg. 2021, 273, 694–700. [Google Scholar] [CrossRef]
- Weiss, A.; Campbell, J.; Ballman, K.V.; Sikov, W.M.; Carey, L.A.; Hwang, E.S.; Poppe, M.M.; Partridge, A.H.; Ollila, D.W.; Golshan, M. Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Ann. Surg. Oncol. 2021, 28, 5960–5971. [Google Scholar] [CrossRef]
- Masuda, N.; Lee, S.J.; Ohtani, S.; Im, Y.H.; Lee, E.S.; Yokota, I.; Kuroi, K.; Im, S.A.; Park, B.W.; Kim, S.B.; et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N. Engl. J. Med. 2017, 376, 2147–2159. [Google Scholar] [CrossRef] [PubMed]
- von Minckwitz, G.; Huang, C.S.; Mano, M.S.; Loibl, S.; Mamounas, E.P.; Untch, M.; Wolmark, N.; Rastogi, P.; Schneeweiss, A.; Redondo, A.; et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N. Engl. J. Med. 2019, 380, 617–628. [Google Scholar] [CrossRef] [PubMed]
- van der Noordaa, M.E.M.; van Duijnhoven, F.H.; Cuijpers, F.N.E.; van Werkhoven, E.; Wiersma, T.G.; Elkhuizen, P.H.M.; Winter-Warnars, G.; Dezentje, V.; Sonke, G.S.; Groen, E.J.; et al. Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer. Br. J. Surg. 2021, 108, 667–674. [Google Scholar] [CrossRef] [PubMed]
- Pesek, S.; Ashikaga, T.; Krag, L.E.; Krag, D. The false-negative rate of sentinel node biopsy in patients with breast cancer: A meta-analysis. World J. Surg. 2012, 36, 2239–2251. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Krag, D.N.; Anderson, S.J.; Julian, T.B.; Brown, A.M.; Harlow, S.P.; Costantino, J.P.; Ashikaga, T.; Weaver, D.L.; Mamounas, E.P.; Jalovec, L.M.; et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010, 11, 927–933. [Google Scholar] [CrossRef] [Green Version]
- Mattar, D.; Di Filippo, A.; Invento, A.; Radice, D.; Burcuta, M.; Bagnardi, V.; Magnoni, F.; Santomauro, G.; Corso, G.; Mazzarol, G.; et al. Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology. Eur. J. Surg. Oncol. 2021, 47, 2499–2505. [Google Scholar] [CrossRef]
- Che Bakri, N.A.; Kwasnicki, R.M.; Khan, N.; Ghandour, O.; Lee, A.; Grant, Y.; Dawidziuk, A.; Darzi, A.; Ashrafian, H.; Leff, D.R. Impact of Axillary Lymph Node Dissection and Sentinel Lymph Node Biopsy on Upper Limb Morbidity in Breast Cancer Patients: A Systematic Review and Meta-Analysis. Ann. Surg. 2023, 277, 572–580. [Google Scholar] [CrossRef]
- Pilger, T.L.; Francisco, D.F.; Candido Dos Reis, F.J. Effect of sentinel lymph node biopsy on upper limb function in women with early breast cancer: A systematic review of clinical trials. Eur. J. Surg. Oncol. 2021, 47, 1497–1506. [Google Scholar] [CrossRef]
- Perenyei, M.; Barber, Z.E.; Gibson, J.; Hemington-Gorse, S.; Dobbs, T.D. Anaphylactic Reaction Rates to Blue Dyes Used for Sentinel Lymph Node Mapping: Systematic Review and Meta-analysis. Ann. Surg. 2021, 273, 1087–1093. [Google Scholar] [CrossRef]
- Fowler, A.M.; Mankoff, D.A.; Joe, B.N. Imaging Neoadjuvant Therapy Response in Breast Cancer. Radiology 2017, 285, 358–375. [Google Scholar] [CrossRef] [Green Version]
- Yuan, Y.; Chen, X.S.; Liu, S.Y.; Shen, K.W. Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: A meta-analysis. AJR Am. J. Roentgenol. 2010, 195, 260–268. [Google Scholar] [CrossRef]
- Semiglazov, V. RECIST for Response (Clinical and Imaging) in Neoadjuvant Clinical Trials in Operable Breast Cancer. J. Natl. Cancer Inst. Monogr. 2015, 2015, 21–23. [Google Scholar] [CrossRef] [Green Version]
- Expert Panel on Breast, I.; Slanetz, P.J.; Moy, L.; Baron, P.; diFlorio, R.M.; Green, E.D.; Heller, S.L.; Holbrook, A.I.; Lee, S.J.; Lewin, A.A.; et al. ACR Appropriateness Criteria((R)) Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer. J. Am. Coll. Radiol. 2017, 14, S462–S475. [Google Scholar] [CrossRef] [Green Version]
- Kuerer, H.M.; Rauch, G.M.; Krishnamurthy, S.; Adrada, B.E.; Caudle, A.S.; DeSnyder, S.M.; Black, D.M.; Santiago, L.; Hobbs, B.P.; Lucci, A., Jr.; et al. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann. Surg. 2018, 267, 946–951. [Google Scholar] [CrossRef] [PubMed]
- Hersh, E.H.; King, T.A. De-escalating axillary surgery in early-stage breast cancer. Breast 2022, 62 (Suppl 1), S43–S49. [Google Scholar] [CrossRef]
- Jatoi, I.; Kunkler, I.H. Omission of sentinel node biopsy for breast cancer: Historical context and future perspectives on a modern controversy. Cancer 2021, 127, 4376–4383. [Google Scholar] [CrossRef]
- Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy (ASICS). 2020. Available online: https://clinicaltrials.gov/ct2/show/NCT04225858 (accessed on 1 June 2023).
- Reimer, T.; Glass, A.; Botteri, E.; Loibl, S.; Oreste, D.G. Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial. Cancers 2020, 12, 3698. [Google Scholar] [CrossRef]
- Lyman, G.H.; Temin, S.; Edge, S.B.; Newman, L.A.; Turner, R.R.; Weaver, D.L.; Benson, A.B., 3rd; Bosserman, L.D.; Burstein, H.J.; Cody, H., 3rd; et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 2014, 32, 1365–1383. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Interdisciplinary German S3-Guideline for Screening, Diagnosis, Therapy and Follow-up in Breast Cancer. Version 4.0. 2017.
- Morrow, M. Leveraging the Benefits of Systemic Therapy to Tailor Surgery. JAMA Surg. 2017, 152, 671. [Google Scholar] [CrossRef] [PubMed]
- Samiei, S.; van Nijnatten, T.J.A.; de Munck, L.; Keymeulen, K.; Simons, J.M.; Kooreman, L.F.S.; Siesling, S.; Lobbes, M.B.I.; Smidt, M.L. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy. Ann. Surg. 2020, 271, 574–580. [Google Scholar] [CrossRef] [PubMed]
- Karakatsanis, A.; Eriksson, S.; Pistiolis, L.; Olofsson Bagge, R.; Nagy, G.; Man, V.; Kwong, A.; Warnberg, F.; SentiNot Trialists, G. Delayed Sentinel Lymph Node Dissection in Patients with a Preoperative Diagnosis of Ductal Cancer In Situ by Preoperative Injection with Superparamagnetic Iron Oxide (SPIO) Nanoparticles: The SentiNot Study. Ann. Surg. Oncol. 2023, 30, 4064–4072. [Google Scholar] [CrossRef] [PubMed]
Study | Citation | Study Design | Number of Patients (N) | ypN+ Cases (%) | Comments |
---|---|---|---|---|---|
Tadros A.B et al. | [8] | Prospective cohort | 116 | 0 (0) | pCR |
Barron et al. | [9] | Retrospective | 3240 | 75 (0.03) | pCR |
Zhi-Qiang et al. | [10] | Retrospective | 17 | 0 (0) | pCR |
Samiei et al. | [11] | Retrospective registry | 353 | 4 (1.1) | pCR |
Weiss et al. | [12] | Retrospective | 108 | 4 (3.7) | pCR |
Total | 3834 | 83 (2.16) | Overall ypN+ = 2.16% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Alamoodi, M.; Wazir, U.; Mokbel, K.; Patani, N.; Varghese, J.; Mokbel, K. Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis. Cancers 2023, 15, 3325. https://doi.org/10.3390/cancers15133325
Alamoodi M, Wazir U, Mokbel K, Patani N, Varghese J, Mokbel K. Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis. Cancers. 2023; 15(13):3325. https://doi.org/10.3390/cancers15133325
Chicago/Turabian StyleAlamoodi, Munaser, Umar Wazir, Kinan Mokbel, Neill Patani, Jajini Varghese, and Kefah Mokbel. 2023. "Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis" Cancers 15, no. 13: 3325. https://doi.org/10.3390/cancers15133325